The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The relationship between metastatic sites and progression free survival of nivolumab in non-small cell lung cancer patients.
 
Motohiro Tamiya
Speakers' Bureau - Asahi Kasei; AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Mexico); Ono Pharmaceutical
 
Akihiro Tamiya
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Mexico) (Inst); Ono Pharmaceutical (Inst)
 
Hidekazu Suzuki
Speakers' Bureau - Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Takako Inoue
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical
 
Yoshihiko Taniguchi
No Relationships to Disclose
 
Kenji Nakahama
No Relationships to Disclose
 
Takayuki Shiroyama
No Relationships to Disclose
 
Shun-ichi Isa
No Relationships to Disclose
 
Kazumi Nishino
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan
 
Norio Okamoto
Speakers' Bureau - AstraZeneca Japan
 
Toru Kumagai
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Ono Pharmaceutical
 
Tomonori Hirashima
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shinji Atagi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Fumio Imamura
Honoraria - Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)